Announcement on the Capital Increase of Shanghai North Carolina by Subsidiary Peak Pharmaceutical
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 公告编号:临2018-025
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
关于子公司尖峰药业对上海北卡增资的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
l拟增资的控股子公司名称:上海北卡医药技术有限公司
l拟增资金额:5000万元
l出资方式:拟使用自筹资金进行增资
一、对外投资概述
(一)2018年8月3日,本公司控股子公司浙江尖峰药业有限公司(以下简称:尖峰药业)和自然人吴江与康立涛、李倩、郑亚玲及上海北卡医药技术有限公司(以下简称:上海北卡)签订《股权增资协议》,对尖峰药业的控股子公司上海北卡进行增资,增资价格:以坤元资产评估有限公司所出具了《资产评估报告》(坤元评报〔2017〕1-37号)为基础,以2018年1月19日尖峰药业与各方签订的《关于上海北卡医药技术有限公司之增资和股权转让协议》中约定的增资价格为准,确定为:每1元注册资本的认缴价格为11.53元。尖峰药业出资人民币5000万元,自然人吴江出资人民币1000万元,上海北卡的其他股东放弃参与本次增资。
增资完成后,上海北卡注册资本由原来的1755.55万元增加至2275.93万元,其中尖峰药业占61.48%,康立涛占18.42%,李倩占11.46%,郑亚玲4.83%,吴江3.81%。
(二)董事会审议情况
2018年8月3日,公司以通讯方式召开了第十届董事会第五次会议,公司现有九名董事,全部参加了会议,经审议与表决,董事会以9票同意、0票反对、0票弃权审议并通过了该事项。
(三)根据上海证券交易所《股票上市规则》和公司《章程》等有关规定,公司本次对外投资属董事会权限范围,无需提交股东大会审议。该股权收购事项不属于关联交易,也不构成《上市公司重大资产重组管理办法》规定的重大资产重组情况。
二、新增股东的基本情况
吴江,男,中国国籍,住址:浙江省东阳市吴宁街道东岘新村**幢*号,职业:安徽众望董事长兼总经理。
三、投资标的基本情况
(一)上海北卡的基本情况
1、企业名称:上海北卡医药技术有限公司
2、企业性质:有限责任公司
3、注册地:上海市松江区申港路3802号21幢
4、注册日期:2003年10月20日
5、主要办公地点:上海市松江区申港路3802号21幢
6、法定代表人:蒋晓萌
7、注册资本:1755.55万元
8、经营范围:医药和化学专业技术领域内的技术开发、技术咨询、技术服务、技术转让;机械设备、仪器仪表、食用农产品(不含生猪产品)、化肥、饲料添加剂、化工原料及产品(除危险品)批发零售;医药中间体的开发、销售;从事货物及技术的进出口业务。(依法须经批准的项目,经相关部门批准后方可开展经营活动)
9、股东情况
2018年1月,本公司控股子公司尖峰药业与有关各方签订了协议,以收购股权和增资的方式对上海北卡进行投资。详见本公司于2018年1月20日《关于子公司尖峰药业对外投资的公告》。2018年5月,尖峰药业完成了该投资事宜,上海北卡完成了工商变更登记手续,成为尖峰药业的控股子公司。
|
序号 |
股东名称 |
出资额(万元) |
出资比例(%) |
|
1 |
浙江尖峰药业有限公司 |
965.55 |
55.00 |
|
2 |
康立涛 |
419.26 |
23.88 |
|
3 |
李倩 |
260.74 |
14.85 |
|
4 |
郑亚玲 |
110.00 |
6.27 |
|
|
合计 |
1755.55 |
100.00 |
(二)标的公司2017年和2018年半年度财务报表情况
截至2017年末,上海北卡合并资产总额8801.80万元、负债总额7435.37万元、归属于母公司股东权益1366.43万元;2017年合并营业收入9296.47万元、归属于母公司所有者净利润-475.45万元;
截至2018年6月末,上海北卡合并资产总额12828.90 万元、负债总额3346.36万元、归属于母公司股东权益9482.54万元。2018年1-6月合并营业收入8505.53万元、归属于母公司所有者净利润557.63万元。
2017年度的财务数据经具有证券、期货从业资格的天健会计师事务所(特殊普通合伙)审计,2018年半年度的财务数据未经审计。
四、合作协议的主要内容
尖峰药业(甲方1)和吴江(甲方2)(合称甲方)、上海北卡(乙方或标的公司)和原股东康立涛、李倩、郑亚玲(合称丙方)签订了《关于上海北卡医药技术有限公司之增资协议》。协议的主要内容有:
(一)股权增资方案
1.增资价格
三方同意,本次增资的价格以2018年1月19日甲方1和丙方、海南寰太生物医药产业创业投资基金合伙企业、乙方签订的《关于上海北卡医药技术有限公司之增资和股权转让协议》中约定的增资价格为准,本协议项下的增资价格为:每1元注册资本的认缴价格为11.53元。
2.甲方增资金额
2.1本协议项下,甲方1本次增资额为人民币5000万元。其中,433.65万元记入注册资金,4566.35万元记入资本公积。
甲方2本次增资额为人民币1000万元。其中,86.73万元记入注册资金,913.27万元记入资本公积。
2.2本次增资完成后,乙方的注册资本由1755.55万元增加至2275.93万元,甲方1持有乙方61.48%股权、甲方2持有乙方3.81%股权。
3. 本次增资后乙方的股权结构变化
本次增资完成后,乙方的股东持股比例及出资情况如下:
|
股东名称 |
出资额(万元) |
持有比例(%) |
出资方式 |
|
浙江尖峰药业有限公司 |
1399.20 |
61.48 |
货币 |
|
康立涛 |
419.26 |
18.42 |
货币 |
|
李倩 |
260.74 |
11.46 |
货币 |
|
郑亚玲 |
110.00 |
4.83 |
货币 |
|
吴江 |
86.73 |
3.81 |
货币 |
|
合计 |
2275.93 |
100.00 |
|
4.增资款
本协议项下的增资款,由甲方于本协议生效后的30个工作日内一次性支付至乙方指定的验资账户。
5.股份转让限制
甲2同意,通过协议转让等方式出让公司股份时,视同为“原个人股东”,共同遵守《关于上海北卡医药技术有限公司之增资和股权转让协议》(2018年1月19日签署)的约定。
6.反稀释条款
各方约定,在甲方投资入股后五年内,若乙方公司进行后续增资,其增资价格不得低于甲方本轮增资的价格。
(二)增资手续办理
1. 本协议正式签署之前或当日,乙方应召开股东会,审议本次股权增资事宜。
2. 增资款到位后的30个工作日内,乙方应完成增资的全部法律手续,包括但不限于变更股东名册、修改公司章程、办理工商变更登记手续等。
(三)违约责任
若任何一方违反本协议的约定,给守约方造成实际损失或者丧失投资/融资机会,守约方可要求违约方赔偿经济损失。
(四)争议解决
因本协议所引起的或与本协议有关的任何争议,应协商解决,协商不成的,任何一方都可将争议提交金华市仲裁委员会,根据该会仲裁规则在金华市进行仲裁。
(五)协议的生效、变更与解除
1.本协议的生效需同时满足如下条件:
1.1本协议经协议各方自然人本人或法人的法定代表人签字并盖章;
1.2乙方股东会审议通过本次增资事宜。
1.3甲1的有权部门通过本次增资事宜。
五、本次增资对公司的影响
(一)本次合作是公司加强医药业务板块发展的具体实施,本次增资有利于提升上海北卡的综合实力,增加上海北卡的资金流,为其收购安徽众望制药有限公司提供资金保障。
(二)本次对外投资的资金来源为公司的自筹资金。
(三)本次对外投资对公司当期利润不会造成重大影响。
六、备查文件
公司第十届董事会第五次会议决议
特此公告。
浙江尖峰集团股份有限公司董事会
2018年8月3日
More information
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-31
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-30
Peak Pharmaceutical Becomes National Intellectual Property Demonstration Enterprise
Just one year after it was identified as a national intellectual property advantage enterprise in 2016, "Zhejiang Jianfeng Pharmaceutical Co., Ltd." appeared in the list of national intellectual property demonstration enterprises in 2017 recently announced by the State Intellectual Property Office. As a result, Jianfeng Pharmaceutical has become the first and only national intellectual property demonstration enterprise in Jinhua City. On December 12, the State Intellectual Property Office issued a notice to announce the list of national intellectual property demonstration enterprises and advantageous enterprises in 2017. After the enterprise declaration, the recommendation of the provincial and municipal bureaus, the review of the national bureau, and the public announcement, 182 national intellectual property demonstration enterprises and 816 national intellectual property advantage enterprises have been identified. Including Jianfeng Pharmaceutical, Zhejiang Province has been identified as only 15 national intellectual property demonstration enterprises. With the continuous development of enterprises in recent years, Jianfeng Pharmaceutical has set up a special working organization to cultivate and improve the intellectual property ability from the aspects of strategic management, creation, operation and protection of intellectual property rights. It has successively compiled and implemented 27 procedural documents and 36 forms such as "Intellectual Property Management Manual", "Intellectual Property Reward and Punishment System" and "Trade Secret Management System, and timely according to the policy, the current situation of the enterprise to revise, in order to ensure the compliance and effectiveness of the operation of the system. In 2012 and 2013, Jianfeng Pharmaceutical was successively rated as a patent demonstration enterprise in Jinhua City and Zhejiang Province; in 2013, it won the third prize of Jinhua Patent Implementation Award; in 2016, it passed the certification of intellectual property management system and was identified as a national intellectual property advantage enterprise. Currently, Peak Pharmaceuticals has
2020
07-31
Jianfeng Pharmaceutical Approved to Set up Provincial Research Institute
A few days ago, the relevant departments of Zhejiang Province approved the establishment of the provincial research institute of the peak pharmaceutical company. This is another honor won by Jianfeng Pharmaceutical in the field of independent research and development and scientific and technological innovation after the national postdoctoral research workstation and Zhejiang academician expert workstation. The provincial enterprise research institute is a high-level R & D institution led by the Provincial Department of Science and Technology, jointly recognized by the Provincial Economic and Information Commission and the Provincial Development and Reform Commission. As an important part of the national technological innovation system, the Enterprise Research Institute is the core force of the innovation-driven development of Jianfeng Pharmaceutical, which reflects the ability of Jianfeng Pharmaceutical to set up higher-level and higher-level R & D institutions on its own. the ability to gather and integrate innovation elements, organize scientific and technological innovation, support the sustainable development of enterprises, and lead the technological progress of the industry. As a pharmaceutical enterprise, scientific and technological innovation is the eternal theme of enterprise development, and talent is the key to scientific and technological innovation. Over the years, Jianfeng Pharmaceutical has not only focused on cultivating its own scientific research talents, but also established close cooperative relations with well-known universities and scientific research institutions such as China Pharmaceutical University, Shenyang Pharmaceutical University, Sichuan Antibiotic Industry Research Institute, and also focused on introducing top think tanks. In 2011, Professor Liu Jiajian and his team from Sichuan Institute of Antibiotic Industry were introduced, focusing on the technical research of key intermediates of methoxy cephalosporin. In 2013, Professor Shan Weiguang and his scientific research team from Zhejiang University of Technology were introduced to carry out research on preparation technology. In 2015, Professor Wang Guangji, academician of the Chinese Academy of Engineering, was hired as the chief scientist to organize the research on the anti-drug resistance mechanism of national class I new drugs by intracellular pharmacokinetics. In 2017 with Shanghai antibody
2020
07-31
On November 16, the company held the first extraordinary general meeting of shareholders in 2017, which deliberated and passed the proposal on the expiration of the term of the board of directors and the proposal on the expiration of the term of the board of supervisors, and elected a new board of directors and the board of supervisors. The meeting used a combination of on-site registered voting and online voting to vote on director candidates one by one, and elected Jiang Xiaomeng, Du Zihong, Yu Jianhong, Huang Sujian, Liu Bo, Zhang Guoping, Huang Conyun, Sun Hongbin, and Shi Ximin as the company's tenth board of directors. Directors, of which Huang Conyun, Sun Hongbin, and Shi Ximin are independent directors. The meeting used a combination of on-site registered voting and online voting to vote on supervisor candidates one by one, and elected Chen Tianci, Lu Ruimei, and Shi Fu as supervisors of the company's ninth board of supervisors. Prior to this, the company's trade union held an enlarged meeting of the trade union committee to elect Qin Xuping and Jin Huazhong as employee representative supervisors of the ninth board of supervisors. On the same day, the company's tenth board of directors held its first meeting and elected Jiang Xiaomeng as the chairman of the tenth board of directors. Jiang Xiaomeng, Du Zihong, Huang Sujian, Sun Hongbin and Shi Ximin were elected as members of the Strategy Committee of the 10th Board of Directors, and Jiang Xiaomeng was the chairman of the Strategy Committee. Shi Ximin, Huang Conyun and Jiang Xiaomeng were elected as members of the audit committee of the 10th board of directors, and Shi Ximin was the chairman. Sun Hongbin, Huang Conyun and Jiang Xiaomeng were elected as members of the nomination committee of the 10th board of directors, and Sun Hongbin was the chairman. Huang Cong Yun, Shi Ximin and Du Zihong were elected as members of the remuneration and assessment committee of the 10th board of directors, and Huang Cong Yun was the chairman. The board of directors appointed Yu Jianhong as the general manager of the company and appointed Huang Jinlong.
2020
07-31
Peak natural products pollution control results by the industry attention
As a leader in China's plant extracts industry, Tianjin Jianfeng Natural Products Company has achieved fruitful results in technological innovation. On October 26 and 27, at the 2017 Forum on improving the international competitiveness of China's plant extract industry held in Handan City, Hebei Province, Liu Dan, general manager of the company, delivered a speech entitled "prevention and control of water pollution in the field of plant extraction", introducing the successful experience of sewage treatment in the past five years, which was widely concerned by the participants. In recent years, environmental protection and ecology have become hot words for the development of enterprises and society. Due to the particularity of the plant extraction industry, pollution control in this industry has different characteristics and requirements from ordinary production enterprises. For example, sewage presents higher chroma, extremely low PH value, more suspended solids, high salinity, high concentration of COD, and different sewage water quality of different products. As the earliest enterprise producing opc grape seed extract in China, Natural Products Company has always attached great importance to the pollution control of plant extraction. For example, in the sewage treatment upgrading project implemented in 2016, ozone oxidation and biochemical methods were adopted to remove the remaining organic pollutants, increasing the sewage treatment capacity from 200 cubic meters per day to 500 cubic meters. The latest anaerobic sewage treatment technology is adopted, the COD emission value of the outlet is reduced to 60 mg per liter, which is far lower than the national first-class emission standard of 100 mg per liter. The new system adopts advanced oxidation reaction tower, ozonation method, field energy reactor and sludge adsorption reflux technology, which can quickly and efficiently treat organic pollutants with strong chemical stability without adding any chemicals.
2020
07-31